Home › Compare › GILD vs CP

GILD vs CP: Dividend Comparison 2026

GILD yields 2.34% · CP yields 0.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GILD wins by $4.4K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
CP
CP
● Live price
0.85%
Share price
$77.52
Annual div
$0.66
5Y div CAGR
26%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.8K
Annual income
$1,036.17
Full CP calculator →

Portfolio growth — GILD vs CP

📍 GILD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDCP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + CP cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GILD pays
CP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
CP
Annual income on $10K today (after 15% tax)
$72.42/yr
After 10yr DRIP, annual income (after tax)
$880.74/yr
At 15% tax rate, GILD beats the other by $491.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + CP for your $10,000?

GILD: 50%CP: 50%
100% CP50/50100% GILD
Portfolio after 10yr
$27.0K
Annual income
$1,325.54/yr
Blended yield
4.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
CP
Analyst Ratings
26
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$88.75
+14.5% upside vs current
Range: $85.00 — $93.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
CP buys
0
No recent congressional trades found for GILD or CP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDCP
Forward yield2.34% ✓0.85%
Annual dividend / share$3.19 ✓$0.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%26% ✓
Portfolio after 10y$29.1K ✓$24.8K
Annual income after 10y$1,614.90 ✓$1,036.17
Total dividends collected$7.6K ✓$4.2K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$158.71 ✓$88.75

Year-by-year: GILD vs CP ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrCP PortfolioCP Income/yrGap
1← crossover$10,974$274.45$10,807$107.35+$167.00 → GILD
2$12,073$330.19$11,700$136.62+$373.00 → GILD
3$13,316$398.20$12,694$174.17+$622.00 → GILD
4$14,730$481.49$13,805$222.51+$925.00 → GILD
5$16,345$583.87$15,056$284.95+$1.3K → GILD
6$18,199$710.26$16,476$365.97+$1.7K → GILD
7$20,340$866.96$18,101$471.59+$2.2K → GILD
8$22,826$1,062.22$19,978$610.10+$2.8K → GILD
9$25,731$1,306.80$22,169$792.94+$3.6K → GILD
10$29,147$1,614.90$24,757$1,036.17+$4.4K → GILD

GILD vs CP: Complete Analysis 2026

GILD — Healthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

CP — Stock

Canadian Pacific Kansas City Ltd. engages in the provision of rail freight transportation services. It offers rail services linking Canada, the United States and Mexico. The company was founded on June 22, 2001, and is headquartered in Calgary, Canada.

Full CP Calculator →
📬

Get this GILD vs CP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.